Nocion Therapeutics is a biotechnology company developing small molecules inhibitors of neuroinflammation for cough and itch. Nocion’s first program targets activated airway neurons by targeting entry through nociceptor large pore channels that are open during periods of inflammation that can lead to acute and chronic cough. These molecules become trapped in these activated neurons and inhibit their ability to induce cough. The company recently completed a Phase 1 trial with an inhaled molecule and will have top-line data in chronic cough patients by mid-2021. Nocion also plans to test this program in post-viral acute cough, something that has become more prevalent during the Covid-19 pandemic. The company is based in Waltham, MA, and has in-licensed intellectual property from Harvard University and Boston Children’s Hospital.